Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin in pediatric refractory solid tumors
NCT02082626Phase 1Terminated
- Sponsor
- University of Oklahoma
- Start
- Feb 2014
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eribulin in solid tumor and lymphoma, sponsored by University of Oklahoma. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Feb 2014; status: terminated.
02
Drugs
eribulin
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT02082626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02082626.